Skip to main navigation
Skip to search
Skip to main content
Northwestern Scholars Home
Help & FAQ
Home
Experts
Organizations
Research Output
Grants
Core Facilities
Research Data
Search by expertise, name or affiliation
Timing of administration of glycoprotein IIb-IIIa inhibitors
Dan James Fintel
*
*
Corresponding author for this work
Medicine, Cardiology Division
Research output
:
Contribution to journal
›
Review article
›
peer-review
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Timing of administration of glycoprotein IIb-IIIa inhibitors'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Medicine and Dentistry
Diseases
100%
Adverse Event
100%
Catheterization
100%
Thrombus
100%
Antiplatelet
100%
Invasive Procedure
100%
Heart Muscle Ischemia
100%
Clinical Study
100%
ST Elevation
100%
Percutaneous Coronary Intervention
100%
Eptifibatide
100%
Glycoprotein IIb/IIIa Inhibitors
100%
Clinical Trial
100%
Percutaneous Intervention
100%
Abciximab
100%
Keyphrases
Initial Management
100%
Timing of Administration
100%
Glycoprotein IIb/IIIa Inhibitors
100%
Clinical Trials
50%
Clinical Setting
50%
Treatment Strategy
50%
Clinical Events
50%
Percutaneous Intervention
50%
North America
50%
Adverse Events
50%
Optimal Timing
50%
Interventional Procedures
50%
Invasive Procedures
50%
Catheterization
50%
Coronary Disease
50%
Optimal Duration
50%
Withholding
50%
Initial Treatment
50%
Antiplatelet Therapy
50%
Management Methods
50%
Clinical Comparison
50%
Abciximab
50%
ST-segment Elevation
50%
Eptifibatide
50%
Thrombus Burden
50%
Approved Indication
50%
Head-to-head Studies
50%
Pharmacology, Toxicology and Pharmaceutical Science
Clinical Study
100%
Clinical Trial
100%
Antiplatelet
100%
Adverse Event
100%
Heart Muscle Ischemia
100%
Thrombus
100%
Fibrinogen Receptor
100%
Disease
100%
Abciximab
100%
Eptifibatide
100%